SPONSORED

With Pending FDA Approval(12) and Growing Medical Leaf Support, Rapid Therapeutic Science Laboratories Could Be One of 2021’s Top Companies

U.S. OTC: (RTSL)

News Update June 8, 2021:
Rapid Therapeutics Prepares to Bring Sublingual Spray Products to Market

The Top Reasons to Have Rapid Therapeutic Science Laboratories U.S. OTC: (RTSL) On Your Radar

  1. Rapid Therapeutic Science Laboratories U.S. OTC: (RTSL) looks well-positioned in a medical leaf market expected to balloon to $35.1 billion in the next five years.(1)
  2. Its products deliver measured amounts of cann-a-bi-noids straight to the systemic blood system through the lungs with a short burst of aerosolized medicine.(2)
  3. Its Rxoid Metered Dose Inhaler is 98% bioavailable.(2)
  4. Compared to edibles, a 5mg dose from a Rxoid MDI is approximately 2,000% more efficient in delivering leaf into the bloodstream.(3)
  5. With more states legalizing the use of green leaf, and speculation of legalization at the federal level, there’s growing excitement.(4)

Rapid Therapeutic Science Laboratories U.S. OTC: (RTSL) is racing to meet medical leaf demand for millions of users. With its metered dose inhaler that delivers cannab-inoids straight to the systemic blood system, its product could provide up to 98% bioavailability.

Do the math. Only about 2% of the dose is lost during exhalation.(6)

That alone could unlock a historic opportunity.

In addition, as compared to an edible, a 5mg dose from a Rxoid MDI is approximately 2,000% more efficient in delivering leaf into the bloodstream.

“MDIs deliver Active Pharmaceutical Ingredients (API’s) into the blood stream within seconds of inhalation. RTSL’s MDIs are a safe and convenient replacement for vape pens, tanks, and mods, and deliver a 98% bioavailable dose of leaf,” says Sean Berrier, Sr. VP and Co-founder.(7)

RTSL developed this new method of formulating and manufacturing pressurized metered-dose inhalers (pMDI) that contain and properly aerosolize proprietary formula of one or more canna-binoid compounds. So of course, this data could be game-changing news.

Not to mention, RTSL’s nhāler product line is manufactured in full-compliance with GMP.

There’s a perfect storm of factors driving monumental leaf demand…

For one, there’s a substantial amount of support for legalization.

In fact, a Pew Research Center survey found that 67% of the U.S. supports leaf legalization.(5) In addition, a Gallup survey found that 66% of Americans are in favor of legalization. That’s up from just 60% in 2016.(9)

On top of that, 14% of Americans now use leaf products.(10)

Second of all, there’s significant demand for quick relief and higher levels of bioavailability for those seeking relief from medical and mental health issues.

Lastly, the U.S. may be closer to legalization than we realize. After all, according to Reuters, Senators recently unveiled a draft of a bill for legalization.(15)

All as Leaf Has Been Shown to Reduce Issues of Depression, Anxiety, and Stress

According to a study in the Journal of Affective Disorders, leaf can help reduce depression, anxiety, and stress in the short term.(11)

Plus, demand for medical leaf is accelerating because of other reported health benefits, including:

  • Reduction of arthritis pain
  • Reduction of migraines and other headache issues
  • Reduction of inflammation
  • Reduction of sore muscle discomfort
  • Relief from epilepsy and seizures

Rapid Therapeutic Science Laboratories U.S. OTC: (RTSL) Just Filed With The US FDA

Rapid Therapeutic Science Laboratories recently executed two contracts to conduct Phase 1 human clinical trials with its flagship metered dose inhaler (MDI) containing cann-a-bidiol.(12)

RTSL entered into these two contracts in preparation for filing an Investigational New Dr-ug Application (IND) with the U.S. Food and Dr-ug Administration (FDA). (12)

The planned studies will initially focus on the therapeutic benefits of CB relating to depression, anxiety, insomnia, ADHD, and arthritis/chronic pain. Of importance, the studies will measure blood serum levels (pharmacokinetics) to support clinical observations. RTSL will need to file and obtain approval of the IND by the FDA to begin the planned studies.

In addition, according to Dr. Charles Powell, MD, Chief Medical Officer (CMO):

“Based upon my observation from our clinical experience with this product, we think these studies will translate into concrete data that will ultimately result in Phase 2 and 3 studies which will hopefully lead to a fully approved FDA product.”(12)

Rapid Therapeutic Science Laboratories U.S. OTC: (RTSL): Bringing Its Sublingual Spray Products to Market

RTSL is also preparing to launch a marketing and sales campaign of its recently enhanced sublingual spray line (applied via a spray into the mouth).(14)

These sublingual sprays are made using RTSL’s proprietary pharmaceutical-grade isolates in blends for multiple flavors and terpenes. In addition, the sprays are manufactured on the same equipment as RTSL’s metered-dose inhalers (MDI) in the company’s existing ISO Level 6 laboratory. They also fully comply with Good Manufacturing Practice (GMP) standards.

RTSL’s CEO, Donal R. Schmidt, Jr. stated, “Our decision to file an IND application for our flagship MDI containing cann-a-bidiol, as previously announced, requires we remove this MDI product from the market while the application is pending. Nevertheless, this removal will not affect our use of pure pharmaceutical isolates formulas we have developed or our existing aerosol equipment. In fact, in addition to the sublingual sprays we are preparing to market, we are also testing nasal sprays and topical sprays, using our existing equipment and formulas for planned delivery in the fourth quarter.”(14)

In Addition, Rapid Therapeutic Science Laboratories U.S. OTC: (RTSL) Finalized Lab Work on Formulas

The company announced the completion of lab development on three formulas related to the manufacture of pharmaceutical-grade isolates used in both metered-dose inhalers and other aerosol products.

Two of these formulas were developed for cann-a-bidiol, and one for cann-a-bigerol to initially be used in Metered Dose Inhalers (MDI). One formula is expected to be used in the testing of the MDI, which RTSL plans to submit to the FDA in connection with an Investigational New Dr-ug Application (IND).

Rapid Therapeutic Science Laboratories U.S. OTC: (RTSL) Launched New Lifestyle Brand, “nhāler”

Rapid Therapeutic Science Laboratories also announced a relationship with Ezzey Digital Marketing Agency to launch its new proprietary aerosol inhaler and lifestyle brand, nhāler.(16)

Additionally, the company stated that its new ISO 13485 laboratory is ready to begin manufacturing the nhāler brand.

“Our new laboratory allows RTSL to produce up to 2.9 million nhāler and Rxoid™ MDI per year. In addition, as demand increases, we can scale it to double the output with minimal additional personnel or capital outlay in about 9-12 weeks. It also reduces our manufacturing expenses and is a key process to eventual FDA approval of our MDI product line. Certainly, as we produce other aerosolized products in the future such as prescription medication, we will need this lab. I want to congratulate our team for getting the build-out finished on time and under budget.”(13)

The Top Reasons to Have Rapid Therapeutic Science Laboratories U.S. OTC: (RTSL) On Your Radar

  1. Rapid Therapeutic Science Laboratories U.S. OTC: (RTSL) looks well-positioned in a medical leaf market expected to balloon to $35.1 billion in the next five years.(1)
  2. Its products deliver measured amounts of cann-a-bi-noids straight to the systemic blood system through the lungs with a short burst of aerosolized medicine.(2)
  3. Its Rxoid Metered Dose Inhaler is 98% bioavailable.(2)
  4. Compared to edibles, a 5mg dose from a Rxoid MDI is approximately 2,000% more efficient in delivering leaf into the bloodstream.(3)
  5. With more states legalizing the use of green leaf, and speculation of legalization at the federal level, there’s growing excitement.(4)

Source 1: https://bit.ly/3z2bmsQ
Source 2: https://www.biospace.com/article/releases/rapid-therapeutic-announces-major-contract-is-increased-by-150-percent-to-250-000-metered-dose-inhalers-/
Source 3: https://www.rxoid.com/mdi-fda-approve-meter-device/
Source 4: https://bit.ly/3k2KRwX
Source 5: https://pewrsr.ch/3snBfR8
Source 6: http://www.wallstreetresearcher.com/Images/RTSL%20Investor%20Presentation_06102020.pdf
Source 7: https://www.globenewswire.com/fr/news-release/2020/06/22/2051243/0/en/Rapid-Therapeutic-Science-Laboratories-Inc-Highlighted-in-Research-Report-Released-by-Emerald-Equity-Research-LLC.html
Source 8: https://bit.ly/3g8HcMM
Source 9: https://bit.ly/3z0LSfe
Source 10: https://news.gallup.com/poll/263147/americans-say-cbd-products.aspx
Source 11: https://www.sciencedirect.com/science/article/pii/S0165032718303100
Source 12: https://finance.yahoo.com/news/rapid-therapeutic-prepares-file-investigational-110000006.html
Source 13: https://www.globenewswire.com/news-release/2020/08/18/2079793/0/en/Rapid-Therapeutic-Announces-Completion-of-New-ISO-13485-Laboratory.html
Source 14: https://finance.yahoo.com/news/rapid-therapeutic-prepares-bring-sublingual-110000415.html
Source 15: https://reut.rs/3spS7Xn
Source 16: https://www.globenewswire.com/en/news-release/2020/08/06/2074055/0/en/Rapid-Therapeutic-Science-Laboratories-RTSL-Inc-engages-Ezzey-Digital-Marketing-Agency-to-Launch-its-New-Lifestyle-Brand-nh%C4%81ler.html

OTC:RTSL
Company Contact

5580 Peterson Ln., Suite 200
Dallas, TX 75240
rtslco.com
(800) 497-6059
[email protected]

What They Do

Rapid Therapeutic Science Laboratories, Inc. holds a sublicense agreement to access to certain technology regarding the RxoidTM metered dose inhaler (TMDI). The TMDI is a medical technology that delivers medication directly to a user’s blood stream through the pulmonary tract. The company was formerly known as Holly Brothers Pictures, Inc. and changed its name to Rapid Therapeutic Science Laboratories, Inc. in January 2020. Rapid Therapeutic Science Laboratories, Inc. was incorporated in 2013 and is based in Dallas, Texas.